• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

kinase inhibitor

Graphic image of a pen signing a signature while two strangelooking business people cheer
Biotech

Merck inks Keytruda supply pact to support Exelixis cancer trial

Securing supplies of subcutaneous Keytruda completes the trio of contributors needed to run the colorectal cancer trial.
Nick Paul Taylor May 19, 2026 9:38am
illustration of venture capital investment funding

Incyte vets raise $102M to create better PARP, PI3K drugs

Jan 24, 2024 8:38am
breast cancer mammogram

Roche’s breast cancer drug hits primary endpoint in phase 3

Dec 5, 2023 4:12am
BeiGenes facility in Beijing

BeiGene offers up $1.3B in biobucks for preclinical cancer drug

Nov 21, 2023 7:13am
Roche building

Roche pays $70M for HER2 breast cancer brain metastases prospect

May 9, 2023 6:30am
Joe Jimenez

Aditum finds twist on old idea, paying $10M for BTK inhibitor

Apr 28, 2023 6:11am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings